ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0956

An IL-18-Containing Five-Gene Signature Distinguishes Histologically Identical Dermatomyositis and Lupus Erythematosus Skin Lesions
Abstract Number: 1413

An Imbalance Between Regulatory and Inflammatory T Cell Subsets Distinguishes Systemic Autoimmune Rheumatic Disease Patients from Asymptomatic ANA+ Individuals
Abstract Number: 1240

An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis
Abstract Number: 1589

An Initiative to Improve Timely Glucocorticoid Tapering in Vasculitis
Abstract Number: 1860

An Integrative Approach to Identify Heritable and De Novo Genomic Variations in Psoriatic Arthritis Mutilans and Understand Its Systems Biology
Abstract Number: PP09

An Integrative Approach to Managing Rheumatoid Arthritis (RA): Healing the Body, Mind & Spirit
Abstract Number: 0024

An International Delphi Consensus on Non-pharmacological Interventions for Fibromyalgia
Abstract Number: 1725

An Investigation of the Relationship Between Patient Reported Outcomes and Biomarkers in a Community Rheumatology Practice
Abstract Number: 1647

An Oleuropein-based Dietary Supplement Improves Joint Function in Older People with High Knee Joint Pain
Abstract Number: 0286

An SLE-linked ITGAM Gene Variant Changes Mac-1 Structure, Signaling, and Surface Expression and Enhances IFNg Production and Antigen Presentation by B Cells
Abstract Number: 0663

Analysis of Common Gout Comorbidities in the UK Biobank Cohort Reveals Sex-Specific Effects and Genetic Differentiation
Abstract Number: 0079

Analysis of COVID-19 and Rheumatology Twitter Activity During the Pandemic Months
Abstract Number: 1203

Analysis of the Impact of Tofacitinib Treatment on Weight in Patients with Rheumatoid Arthritis
Abstract Number: 0131

Analysis of the Total Body Composition in a Cohort of Patients with Elderly Onset Arthritis
Abstract Number: 1942

Analysis of Vasculitis Patterns in Patients with Giant Cell Arteritis Compared to Patients with Giant Cell Arteritis and Polymyalgia Rheumatica

« Previous Page
1
…
7
8
9
10
11
…
139
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].